{
    "name": "rituximab-hyaluronidase",
    "comment": "Rx",
    "other_names": [
        "Rituxan Hycela"
    ],
    "classes": [
        "Monoclonal Antibodies",
        "Antineoplastics",
        "Anti-CD20 Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/rituxan-hycela-rituximab-hyaluronidase-1000306",
    "pregnancy": {
        "common": [
            "Based on human data, rituximab can cause adverse developmental outcomes including B-cell lymphocytopenia in infants exposed to rituximab in utero",
            "There are no available data on use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage",
            "Verify pregnancy status in females of reproductive potential prior to initiating therapy"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, IV administration of a rituximab to pregnant cynomolgus monkeys during organogenesis caused lymphoid B-cell depletion in newborn offspring at doses resulting in 80% of the exposure (based on AUC) of those achieved following a dose of 2 g in humans",
                    "Reduced fetal weight and increased fetal lethality were observed following SC administration of hyaluronidase human in mice at a dose >2700 times higher than the human dose"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of childbearing potential should use effective contraception during treatment and for 12 months following treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of rituximab or hyaluronidase human in human milk, the effect on the breastfed infant, or the effect on milk production",
            "However, rituximab is detected in the milk of lactating cynomolgus monkeys, and IgG is present in human milk",
            "Rituximab reported to be excreted at low concentrations in human breast milk; advise a lactating woman not to breastfeed during treatment and for at least 6 months after last dose due to potential for serious adverse reactions in breastfed children"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Severe mucocutaneous reactions",
                    "description": [
                        "Severe, including fatal, mucocutaneous reactions reported including paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis",
                        "Discontinue drug if severe mucocutaneous reaction occurs"
                    ]
                },
                {
                    "type": "Progressive multifocal leukoencephalopathy",
                    "description": [
                        "Progressive multifocal leukoencephalopathy (PML), including fatal PML, reported"
                    ]
                },
                {
                    "type": "Reactivation of hepatitis B",
                    "description": [
                        "Reactivation of hepatitis B virus (HBV) infection reported, including deaths",
                        "Screen all patients for HBV infection before initiating drug by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc)",
                        "Consult with hepatitis experts regarding monitoring and use of HBV antiviral therapy when screening identifies patients at risk of HBV reactivation due to evidence of prior HBV infection",
                        "Monitor patients with evidence of prior HBV infection for clinical and laboratory signs of hepatitis B or HBV reactivation during therapy and for several months thereafter, since reactivations have occurred several months following completion of therapy",
                        "If HBV reactivation develops, discontinue drug immediately and start HBV treatment; also discontinue any chemotherapy until the HBV infection controlled/resolved",
                        "Because of insufficient data, no recommendation can be made regarding the resumption of the drug in patients who develop HBV reactivation hepatitis"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Tumor lysis syndrome (TLS) can occur within 12-24 hr after administration; administer aggressive IV hydration and antihyperuricemic therapy in patients at high risk for TLS; correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated",
                "Cardiac adverse reactions (eg, ventricular fibrillation, myocardial infarction, cardiogenic shock) may occur; discontinue treatment for serious or life-threatening cardiac arrhythmias; perform cardiac monitoring during and after all administrations for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina",
                "Severe, including fatal, renal toxicity can occur after administration; closely monitor for signs of renal failure and discontinue treatment in patients with a rising serum creatinine or oliguria",
                "Abdominal pain, bowel obstruction, and bowel perforation can occur in patients receiving rituximab-containing products, in combination with chemotherapy; in postmarketing reports, the mean time to documented gastrointestinal perforation was 6 days; evaluate if symptoms of obstruction such as abdominal pain or repeated vomiting occur",
                "Safety of immunization with live viral vaccines following rituximab-containing chemotherapy has not been studied, and vaccination with live virus vaccines is not recommended before or during treatment",
                "Based on human data, rituximab-containing products can cause fetal harm due to B-cell lymphocytopenia in infants exposed to rituximab in utero (see Pregnancy)"
            ],
            "specific": [
                {
                    "type": "Infections",
                    "description": [
                        "Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of rituximab",
                        "Infections reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure)",
                        "New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella-zoster virus, West Nile virus, and hepatitis B and C viruses",
                        "Discontinue treatment for serious infections and institute appropriate anti-infective therapy"
                    ]
                },
                {
                    "type": "Hypersensitivity",
                    "description": [
                        "Rituximab-containing products are associated with hypersensitivity and other administration reactions (eg, cytokine release syndrome, TLS, anaphylactic reactions)",
                        "Severe infusion-related reactions (eg, pulmonary events, fever, chills, rigors, hypotension, urticaria, angioedema) with fatal outcome reported with IV use of rituximab, with an onset ranging within 30-120 minutes after starting the first IV infusion",
                        "Cytokine release syndrome may occur within 1-2 hr of initiating infusion; severe cytokine release syndrome is characterized by severe dyspnea, often accompanied by bronchospasm and hypoxia, in addition to fever, chills, rigors, urticaria, and angioedema",
                        "Local cutaneous reactions may occur more than 24 hr after administration",
                        "During administration, interrupt treatment immediately when observing signs of a severe reaction, and initiate aggressive symptomatic treatment; closely monitor the following patients: those with preexisting cardiac or pulmonary conditions, those who experienced prior cardiopulmonary adverse reactions, and those with high numbers of circulating malignant cells (≥25,000/mm³ )",
                        "Premedicate patients with an antihistamine and acetaminophen prior to each administration; also consider glucocorticoids"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "rituximab-hyaluronidase, adenovirus types 4 and 7 live, oral. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "rituximab-hyaluronidase, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baricitinib",
            "description": {
                "common": "baricitinib, rituximab-hyaluronidase.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "rituximab-hyaluronidase, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "rituximab-hyaluronidase and certolizumab pegol both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "rituximab-hyaluronidase, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "rituximab-hyaluronidase, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "rituximab-hyaluronidase, influenza virus vaccine quadrivalent, intranasal. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "rituximab-hyaluronidase, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "rituximab-hyaluronidase, measles (rubeola) vaccine. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "rituximab-hyaluronidase, measles mumps and rubella vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "rituximab-hyaluronidase, measles, mumps, rubella and varicella vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of rituximab-hyaluronidase by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "poliovirus vaccine live oral trivalent",
            "description": {
                "common": "rituximab-hyaluronidase, poliovirus vaccine live oral trivalent. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "rituximab-hyaluronidase, rotavirus oral vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "rituximab-hyaluronidase, rubella vaccine. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "rituximab-hyaluronidase, smallpox (vaccinia) vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "rituximab-hyaluronidase, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "rituximab-hyaluronidase, varicella virus vaccine live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "rituximab-hyaluronidase, yellow fever vaccine. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "rituximab-hyaluronidase, zoster vaccine live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "amphotericin B deoxycholate and rituximab-hyaluronidase both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Caution should be exercised when concurrent therapy is used. Patients should be monitored for signs of renal failure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept and rituximab-hyaluronidase both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "rituximab-hyaluronidase, cholera vaccine. immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "cisplatin and rituximab-hyaluronidase both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Potential for renal toxicity when used in combination with cisplatin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "rituximab-hyaluronidase decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "denosumab",
            "description": {
                "common": "rituximab-hyaluronidase, denosumab. Other (see comment). Use Caution/Monitor. \nComment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of rituximab-hyaluronidase by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "rituximab-hyaluronidase increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis A vaccine inactivated",
            "description": {
                "common": "rituximab-hyaluronidase, hepatitis A vaccine inactivated. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis a/b vaccine",
            "description": {
                "common": "rituximab-hyaluronidase, hepatitis a/b vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis b vaccine",
            "description": {
                "common": "rituximab-hyaluronidase, hepatitis b vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "HIV vaccine",
            "description": {
                "common": "rituximab-hyaluronidase, HIV vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "human papillomavirus vaccine, bivalent",
            "description": {
                "common": "rituximab-hyaluronidase, human papillomavirus vaccine, bivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "human papillomavirus vaccine, nonavalent",
            "description": {
                "common": "rituximab-hyaluronidase, human papillomavirus vaccine, nonavalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "human papillomavirus vaccine, quadrivalent",
            "description": {
                "common": "rituximab-hyaluronidase, human papillomavirus vaccine, quadrivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza A (H5N1) vaccine",
            "description": {
                "common": "rituximab-hyaluronidase, influenza A (H5N1) vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine (H5N1), adjuvanted",
            "description": {
                "common": "rituximab-hyaluronidase, influenza virus vaccine (H5N1), adjuvanted. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent",
            "description": {
                "common": "rituximab-hyaluronidase, influenza virus vaccine quadrivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "rituximab-hyaluronidase, influenza virus vaccine quadrivalent, adjuvanted. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, cell-cultured",
            "description": {
                "common": "rituximab-hyaluronidase, influenza virus vaccine quadrivalent, cell-cultured. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent",
            "description": {
                "common": "rituximab-hyaluronidase, influenza virus vaccine trivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "rituximab-hyaluronidase, influenza virus vaccine trivalent, adjuvanted. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ioversol",
            "description": {
                "common": "ioversol and rituximab-hyaluronidase both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "rituximab-hyaluronidase and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "Japanese encephalitis virus vaccine",
            "description": {
                "common": "rituximab-hyaluronidase, Japanese encephalitis virus vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine, rituximab-hyaluronidase.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration with mechlorethamine may increase the risk of immunosuppression and myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "poliovirus vaccine inactivated",
            "description": {
                "common": "rituximab-hyaluronidase decreases effects of poliovirus vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response may be suboptimal. Patients on chemotherapy with anti-B cell antibodies should wait =6 months after therapy before being vaccinated with inactivated vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and rituximab-hyaluronidase both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies vaccine",
            "description": {
                "common": "rituximab-hyaluronidase, rabies vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies vaccine chick embryo cell derived",
            "description": {
                "common": "rituximab-hyaluronidase, rabies vaccine chick embryo cell derived. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and rituximab-hyaluronidase both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "rituximab-hyaluronidase decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, rituximab-hyaluronidase.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, rituximab-hyaluronidase.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and rituximab-hyaluronidase both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine recombinant",
            "description": {
                "common": "rituximab-hyaluronidase, zoster vaccine recombinant. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methotrexate",
            "description": {
                "common": "methotrexate and rituximab-hyaluronidase both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Percentages are for all grades of toxicity unless otherwise noted",
            "percent": "32"
        },
        {
            "name": "Neutropenia",
            "percent": "31"
        },
        {
            "name": "Nausea",
            "percent": "25"
        },
        {
            "name": "Constipation",
            "percent": "23"
        },
        {
            "name": "Cough",
            "percent": "20"
        },
        {
            "name": "Fatigue",
            "percent": "18"
        },
        {
            "name": "Diarrhea",
            "percent": "17"
        },
        {
            "name": "Asthenia",
            "percent": "15"
        },
        {
            "name": "Pyrexia",
            "percent": "15"
        },
        {
            "name": "Anemia",
            "percent": "14"
        },
        {
            "name": "Abdominal pain",
            "percent": "14"
        },
        {
            "name": "Vomiting",
            "percent": "14"
        },
        {
            "name": "Alopecia",
            "percent": "16"
        },
        {
            "name": "Paresthesia",
            "percent": "13"
        },
        {
            "name": "Injection site erythema",
            "percent": "13"
        },
        {
            "name": "Arthralgia",
            "percent": "12"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "11"
        },
        {
            "name": "Dyspnea",
            "percent": "11"
        },
        {
            "name": "Pneumonia",
            "percent": "31"
        },
        {
            "name": "Neutropenia",
            "percent": "24"
        },
        {
            "name": "lopecia",
            "percent": "23"
        },
        {
            "name": "Anemia",
            "percent": "22"
        },
        {
            "name": "Nausea",
            "percent": "19"
        },
        {
            "name": "Fatigue",
            "percent": "15"
        },
        {
            "name": "Constipation",
            "percent": "14"
        },
        {
            "name": "Diarrhea",
            "percent": "14"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "14"
        },
        {
            "name": "Decreased neutrophil count",
            "percent": "13"
        },
        {
            "name": "Pyrexia",
            "percent": "12"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "11"
        },
        {
            "name": "Cough",
            "percent": "11"
        },
        {
            "name": "Asthenia",
            "percent": "11"
        },
        {
            "name": "Vomiting",
            "percent": "65"
        },
        {
            "name": "Neutropenia",
            "percent": "38"
        },
        {
            "name": "Nausea",
            "percent": "32"
        },
        {
            "name": "Pyrexia",
            "percent": "26"
        },
        {
            "name": "Injection site erythema",
            "percent": "24"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "21"
        },
        {
            "name": "Vomiting",
            "percent": "19"
        },
        {
            "name": "Leukopenia",
            "percent": "16"
        },
        {
            "name": "Injection site pain",
            "percent": "15"
        },
        {
            "name": "Erythema",
            "percent": "13"
        },
        {
            "name": "Anemia",
            "percent": "13"
        },
        {
            "name": "Chills",
            "percent": "13"
        },
        {
            "name": "Cough",
            "percent": "13"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "12"
        },
        {
            "name": "Rash",
            "percent": "12"
        },
        {
            "name": "Diarrhea",
            "percent": "11"
        },
        {
            "name": "Fatigue",
            "percent": "11"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "10"
        },
        {
            "name": "Bone pain",
            "percent": "10"
        },
        {
            "name": "Extremity pain",
            "percent": "10"
        },
        {
            "name": "Pruritus",
            "percent": "10"
        },
        {
            "name": "Rash",
            "percent": "9"
        },
        {
            "name": "Erythema",
            "percent": "9"
        },
        {
            "name": "Back pain",
            "percent": "9"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "9"
        },
        {
            "name": "Insomnia",
            "percent": "8"
        },
        {
            "name": "Dyspepsia",
            "percent": "8"
        },
        {
            "name": "Chills",
            "percent": "8"
        },
        {
            "name": "Injection site pain",
            "percent": "8"
        },
        {
            "name": "Chills",
            "percent": "8"
        },
        {
            "name": "Bronchitis",
            "percent": "8"
        },
        {
            "name": "Urinary tract infection",
            "percent": "8"
        },
        {
            "name": "Muscle spasms",
            "percent": "8"
        },
        {
            "name": "Myalgia",
            "percent": "7"
        },
        {
            "name": "Sinusitis",
            "percent": "7"
        },
        {
            "name": "Dizziness",
            "percent": "7"
        },
        {
            "name": "Insomnia",
            "percent": "6"
        },
        {
            "name": "Stomatitis",
            "percent": "6"
        },
        {
            "name": "Hypertension",
            "percent": "5"
        },
        {
            "name": "Conjunctivitis",
            "percent": "5"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "5"
        },
        {
            "name": "Peripheral edema",
            "percent": "5"
        },
        {
            "name": "Mucosal inflammation",
            "percent": "4"
        },
        {
            "name": "Influenza",
            "percent": "3"
        },
        {
            "name": "Influenza",
            "percent": "3-4"
        },
        {
            "name": "like illness",
            "percent": "2"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "3-4"
        },
        {
            "name": "Grade",
            "percent": "2"
        },
        {
            "name": "Diarrhea",
            "percent": "3-4"
        },
        {
            "name": "Grade",
            "percent": "1"
        },
        {
            "name": "Asthenia",
            "percent": "3-4"
        },
        {
            "name": "Grade",
            "percent": "1"
        },
        {
            "name": "Chest pain",
            "percent": "3-4"
        },
        {
            "name": "Grade",
            "percent": "1"
        },
        {
            "name": "Dyspnea",
            "percent": "3-4"
        },
        {
            "name": "Grade",
            "percent": "1"
        },
        {
            "name": "Hypertension",
            "percent": "9"
        },
        {
            "name": "Grade",
            "percent": "8"
        },
        {
            "name": "Paresthesia",
            "percent": "8"
        },
        {
            "name": "Mucosal inflammation",
            "percent": "8"
        },
        {
            "name": "Peripheral edema",
            "percent": "8"
        },
        {
            "name": "Decreased weight",
            "percent": "7"
        },
        {
            "name": "Decreased appetite",
            "percent": "7"
        },
        {
            "name": "Abdominal pain",
            "percent": "7"
        },
        {
            "name": "Pneumonia",
            "percent": "7"
        },
        {
            "name": "Leukopenia",
            "percent": "7"
        },
        {
            "name": "Decreased WBC count",
            "percent": "6"
        },
        {
            "name": "Insomnia",
            "percent": "6"
        },
        {
            "name": "Stomatitis",
            "percent": "6"
        },
        {
            "name": "Headache",
            "percent": "5"
        },
        {
            "name": "Dyspnea",
            "percent": "5"
        },
        {
            "name": "Dyspepsia",
            "percent": "5"
        },
        {
            "name": "Lymphopenia",
            "percent": "9"
        },
        {
            "name": "Decreased lymphocyte count",
            "percent": "9"
        },
        {
            "name": "Abdominal pain",
            "percent": "8"
        },
        {
            "name": "Arthralgia",
            "percent": "8"
        },
        {
            "name": "Constipation",
            "percent": "8"
        },
        {
            "name": "Asthenia",
            "percent": "8"
        },
        {
            "name": "Respiratory tract infection",
            "percent": "7"
        },
        {
            "name": "Pruritus",
            "percent": "7"
        },
        {
            "name": "Bronchitis",
            "percent": "7"
        },
        {
            "name": "Extremity pain",
            "percent": "6"
        },
        {
            "name": "Headache",
            "percent": "6"
        },
        {
            "name": "Bone pain",
            "percent": "4"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "2"
        },
        {
            "name": "Dyspnea",
            "percent": "2"
        },
        {
            "name": "Urinary tract infection",
            "percent": "1"
        },
        {
            "name": "Pneumonia",
            "percent": "1"
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Skin",
            "percent": null
        },
        {
            "name": "Severe mucocutaneous reactions",
            "percent": null
        },
        {
            "name": "pyoderma gangrenosum",
            "percent": null
        },
        {
            "name": "including genital presentation",
            "percent": null
        }
    ]
}